Keqing moved to England from Beijing in 1997, joining the University of Birmingham as a post-graduate student. In 1998 she was award a Masters in Immunology with Distinction and a University-funded PhD, which she was awarded in 2002.
Keqing has extensive postdoctoral research experience in immunology, inflammation and the vascular biology of pregnancy. For the last four years, she has focused on pregnancy-associated complications, funded through a MRC programme grant. Her pregnancy studies identified hydrogen sulphide (H2S) as an important regulator of the placental vasculature development and showed that a deficiency in its production induces preeclampsia-like features. This research provided the first direct evidence that a decrease in placenta growth factor in first trimester, which is associated with poor pregnancy outcome, may stem from H2S/CSE dysregulation. Furthermore, this study identified H2S as a potential new target for therapeutic intervention against preeclampsia and intrauterine fetal growth restriction. This work was published in the June edition of the prestigious journal Circulation (N.B. Add links to paper). Wang is also listed as a co-inventor on a recent patent application filed by the University.